12 Health Care Stocks Moving In Tuesday's Intraday Sessionbenzinga_article·Jul 14 at 12:05 PMGALT+1.45%CARL-1.00%
U.S. stock market midday update: Galectin Therap up 16.74%, active funds but no news catalystPrice Alert·Jul 14 at 10:53 AMGALT+1.45%
Galectin Therapeutics posts corporate presentation highlighting belapectin program for MASH cirrhosis, portal hypertensionPUBT·Jul 14 at 08:53 AMGALT+1.45%
Top Biotech Gainers: QTTB Sends Strong SIGNAL; AMWL And SI In Focusrttnews·Jul 13 at 09:35 PMAGEN-5.33%SI+1.53%
Galectin Therapeutics CMO Jamil Khurram disposes of common shares worth $262,943PUBT·Jun 30 at 06:23 PMGALT+1.45%
Top 3 Health Care Stocks That May Keep You Up At Night In Junebenzinga_article·Jun 30 at 07:55 AMGALT+1.45%DFTX+0.62%
Galectin Therapeutics CMO Jamil Khurram disposes of 7,557 common shares worth $23,728.98PUBT·Jun 25 at 03:07 PMGALT+1.45%
Top Biotech Gainers: PLSM Inks Virtual Maternity Care Deal, ICCM Turns Heads, SLN Hits New Highrttnews·Jun 24 at 10:52 PMPLSM-4.37%NVCT-4.02%
Top Biotech Gainers: BOLD Begins Anew, MNPR NDA Filing On Track, GALT Soars On FDA Alignmentrttnews·Jun 23 at 10:15 PMGALT+1.45%EDSA-6.18%
Galectin Therapeutics shares are trading higher after the company announced feedback from its recent in-person Type C meeting with the FDA supporting the advancement of belapectin for the treatment of patients with metabolic dysfunction-associated steatohepatitis cirrhosis and portal hypertension.benzinga_article·Jun 23 at 10:25 AMGALT+1.45%
Galectin, FDA agree on late-stage trial design for MASH therapybusinessinsider·Jun 23 at 08:00 AMGALT+1.45%
Galectin Therapeutics to file Phase 3 belapectin protocol in Q3 2026 for MASH cirrhosis, portal hypertensionPUBT·Jun 23 at 06:51 AMGALT+1.45%
Key facts: GALT: Belapectin lowers stiffness; funding May 2027; Q1 lossTradingView·May 16 at 02:14 AMGALT+1.45%VHT+0.63%
